News
10-23-2013, 12:24 AM
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
More... (http://www.news-medical.net/news/20131023/New-PARP-inhibitor-shows-early-responses-in-patients-with-advanced-BRCA-related-cancers.aspx)
More... (http://www.news-medical.net/news/20131023/New-PARP-inhibitor-shows-early-responses-in-patients-with-advanced-BRCA-related-cancers.aspx)